Research Papers:
MiR-148a increases glioma cell migration and invasion by downregulating GADD45A in human gliomas with IDH1 R132H mutations
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1910 views | HTML 2590 views | ?
Abstract
Daming Cui1,*, Pandey Sajan1,*, Jinlong Shi2, Yiwen Shen3, Ke Wang1, Xianyu Deng1, Lin Zhou1, Pingping Hu1, Liang Gao1
1Department of Neurosurgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, People’s Republic of China
2Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, People’s Republic of China
3Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200070, People’s Republic of China
*These two authors contributed equally to this paper
Correspondence to:
Liang Gao, email: [email protected]
Keywords: GADD45A, miR-148a, β-catenin, migration, invasion
Received: August 02, 2016 Accepted: February 13, 2017 Published: March 03, 2017
ABSTRACT
High-grade gliomas are severe tumors with poor prognosis. An R132H mutation in the isocitrate dehydrogenase (IDH1) gene prolongs the life of glioma patients. In this study, we investigated which genes are differentially regulated in IDH1 wild type (IDH1WT) or IDH1 R132H mutation (IDH1R132H) glioblastoma cells. Growth arrest and DNA-damage-inducible protein (GADD45A) was downregulated and microRNA 148a (miR-148a) was upregulated in in IDH1R132H human glioblastomas tissues. The relationship between GADD45A and miR-148a is unknown. In vitro experiments showed that GADD45A negatively regulates IDH1R132H glioma cell proliferation, migration, and invasion, and neurosphere formation in IDH1R132H glioblastoma stem cells (GSC). In addition, a human orthotopic xenograft mouse model showed that GADD45A reduced tumorigenesis in vivo. Our findings demonstrated that miR-148a promotes glioma cell invasion and tumorigenesis by downregulating GADD45A. Our findings provide novel insights into how GADD45A is downregulated by miR-148a in IDH1R132H glioma and may help to identify therapeutic targets for the effective treatment of high-grade glioma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15867